Sandbox:farnaz: Difference between revisions

Jump to navigation Jump to search
Line 14: Line 14:


=== Type 2: ===
=== Type 2: ===
The primary therapy for MS may include:<ref name="pmid25095894">{{cite journal| author=Kamm CP, Uitdehaag BM, Polman CH| title=Multiple sclerosis: current knowledge and future outlook. | journal=Eur Neurol | year= 2014 | volume= 72 | issue= 3-4 | pages= 132-41 | pmid=25095894 | doi=10.1159/000360528 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25095894  }} </ref>
The primary therapy for MS may include:<ref name="pmid25095894">{{cite journal| author=Kamm CP, Uitdehaag BM, Polman CH| title=Multiple sclerosis: current knowledge and future outlook. | journal=Eur Neurol | year= 2014 | volume= 72 | issue= 3-4 | pages= 132-41 | pmid=25095894 | doi=10.1159/000360528 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25095894 }} </ref><ref name="pmid29270309">{{cite journal| author=Schwartz K, Wymbs NF, Huang H, Mealy MA, Pardo CA, Zackowski K et al.| title=Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis. | journal=Mult Scler J Exp Transl Clin | year= 2017 | volume= 3 | issue= 4 | pages= 2055217317740145 | pmid=29270309 | doi=10.1177/2055217317740145 | pmc=5731631 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29270309 }} </ref>
*B-interferon
*B-interferon
*Teleflunomide
*Teleflunomide

Revision as of 15:50, 26 January 2018


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farnaz Khalighinejad, MD [2]

Overview

MS is known as multiple sclerosis.

Multiple Sclerosis

ajksfshvanivlk

Type 1:

asdad

Type 2:

The primary therapy for MS may include:[1][2]

  • B-interferon
  • Teleflunomide
Cause Symptom Diagnosis Treatment
1
2
3

References

  1. Kamm CP, Uitdehaag BM, Polman CH (2014). "Multiple sclerosis: current knowledge and future outlook". Eur Neurol. 72 (3–4): 132–41. doi:10.1159/000360528. PMID 25095894.
  2. Schwartz K, Wymbs NF, Huang H, Mealy MA, Pardo CA, Zackowski K; et al. (2017). "Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis". Mult Scler J Exp Transl Clin. 3 (4): 2055217317740145. doi:10.1177/2055217317740145. PMC 5731631. PMID 29270309.